All Outputs (4)

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination (2023)
Journal Article
Zaloum, S. A., Wood, C. H., Tank, P., Upcott, M., Vickaryous, N., Anderson, V., …Tallantyre, E. C. (2023). Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal, 29(8), 979-989. https://doi.org/10.1177/13524585231185247

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear. Objective: To report CO... Read More about Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study (2023)
Journal Article
Papathanasiou, A., Hibbert, A., Tallantyre, E., Harding, K., Selvam, A. P., Morgan, M., …Evangelou, N. (2023). Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study. Neurological Sciences, 44(10), 3629-3635. https://doi.org/10.1007/s10072-023-06838-1

Background: Annualized relapse rate (ARR) is used as an outcome measure in multiple sclerosis (MS) clinical trials. Previous studies demonstrated that ARR has reduced in placebo groups between 1990 and 2012. This study aimed to estimate real-world AR... Read More about Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study.

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis (2023)
Journal Article
Dumitrescu, L., Papathanasiou, A., Coclitu, C., Garjani, A., Evangelou, N., Constantinescu, C. S., …Tanasescu, R. (2023). An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 24(4), 495-509. https://doi.org/10.1080/14656566.2023.2178898

Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual disability accrual (related to progressive neurodegeneration and neuroinflammation)... Read More about An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.

Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study (2023)
Journal Article
Tindall, T., Topcu, G., Thomas, S., Bale, C., Evangelou, N., Drummond, A., & das Nair, R. (2023). Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study. Health Expectations, 26(2), 858-868. https://doi.org/10.1111/hex.13711

Background: Diagnosing multiple sclerosis (MS) can be a lengthy process, which can impact psychological wellbeing, condition management, and future engagement with health services. Therefore, providing timely and appropriate emotional support may imp... Read More about Developing a Patient Care Pathway for Emotional Support around the point of Multiple Sclerosis diagnosis: A Stakeholder Engagement Study.